Streetbeat News

SCNLF

Scancell Hldgs Plc

http://www.scancell.co.uk/

CEO

Clifford Holloway

Industry

Research and Development in Biotechnology

Open

0.23

Mkt cap

167M

Volume

250

High

0.23

P/E Ratio

-9.00

52-wk high

0.23

Low

0.18

Div yield

N/A

52-wk low

0.13

Dr. Phil L'Hullier has been appointed as the new CEO of Scancell Holdings PLC, a company specializing in cancer immunotherapy. His tenure begins at a crucial time as the company makes significant clinical progress with its lead asset, SCIB1, a DNA-based cancer vaccine for advanced melanoma.

Portfolio Pulse from

November 18, 2024 | 3:45 pm

Panmure Liberum has reiterated its 'buy' recommendation for Scancell Holdings PLC shares following a positive update from its phase II SCOPE clinical trial for the cancer vaccine SCIB1.

Portfolio Pulse from

November 18, 2024 | 9:45 am

Scancell Holdings PLC's chief scientist praised the 'excellent' results from the SCOPE trial for advanced melanoma, which tested the SCIB1 immunotherapy in combination with checkpoint inhibitors ipilimumab and nivolumab.

Portfolio Pulse from

November 18, 2024 | 7:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.